SUNHO（China）BioPharmaceutical CO., Ltd.

SUNHO (China) BioPharmaceutical is a Chinese biotech company with limited publicly available information, presenting significant due diligence challenges for potential US partners. While the company appears clear from current BIOSECURE designations, the lack of transparency regarding corporate structure, pipeline, and leadership raises concerns about deal readiness. US BD teams should approach with caution and expect extensive information gathering requirements before meaningful partnership discussions can proceed.

Structure: Corporate structure is unclear due to limited public disclosure, which is concerning for a company seeking international partnerships. The absence of subsidiary information and ownership details suggests either a simple operating structure or inadequate transparency for cross-border deal-making. Due diligence will require extensive primary research to map actual corporate structure and identify potential VIE arrangements or complex holding patterns.